# NCT04115631 (NCT04115631)

> A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04115631
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: ECOG-ACRIN Cancer Research Group
- Conditions: Liver Lymphoma; Mantle Cell Lymphoma
- Interventions: Acalabrutinib; Bendamustine; Bendamustine Hydrochloride; Cytarabine; Rituximab
- Enrollment: 360
- Primary outcome: Composite of positron emission tomography (PET)/computed tomography (CT) complete response (CR) and peripheral blood (PB) minimal residual disease (MRD) negative rate

## Commentary we found

- YouTube: 4
- Podcasts: 3
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04115631

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04115631", "email": "<work email>"}; the inbox owner confirms by the emailed link.